15-methoxy-pentadec-1-yne | 958867-22-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 15-methoxy-pentadec-1-yne
• 英文别名: 15-Methoxypentadec-1-yne；15-methoxypentadec-1-yne
• CAS: 958867-22-6
• 化学式: C₁₆H₃₀O
• 分子量: 238.414
• InChiKey: QZBMZGWKXUWVSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  17
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  L-2',3'-dideoxy-5-iodo-uridine 、 15-methoxy-pentadec-1-yne 在 copper(l) iodide 、 四(三苯基膦)钯 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 23.0h， 生成 Cf 3254
  参考文献：
  名称：

  CHEMICAL COMPOUNDS

  摘要：

  在碱基部分上含有6-取代基的3-(2′,3′-二脱氧-β-L-呋喃核糖基)[2,3-d]嘧啶-2(3H)-酮衍生物显示出抗病毒特性，特别是对天花病毒和麻疹病毒。这些化合物具有非自然的L-核糖立体化学结构。

  公开号：

  US20130012468A1
• 作为产物：
  描述：

  14-十五炔-1-醇 在 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 18.0h， 生成 15-methoxy-pentadec-1-yne
  参考文献：
  名称：

  Novel Antiviral Activity of l-Dideoxy Bicyclic Nucleoside Analogues versus Vaccinia and Measles Viruses in Vitro

  摘要：

  Dideoxy bicyclic pyrimidine nucleoside analogues (ddBCNAs) with D-chirality have previously been described by us to inhibit replication of human cytomegalovirus. We herein report for the first time that activity against vaccinia virus (VACV) was achieved using novel L-analogues. A structure-activity relationship was established: Antiviral activity versus VACV was highest with an ether side chain with an optimum of n-C9H18-O-n-C5H11. This gave an IC50 of 190 nM, a 60-fold enhancement over the FDA-approved antiviral cidofovir. Interestingly, L-ddBCNAs also inhibit wild type measles virus syncytia formation with a TCID50 of 7.5 mu M for the lead compound. We propose that L-ddBCNAs represent significant innovative antiviral candidates versus measles and poxviruses, and we suggest a mechanism of action versus one or more cellular targets that are essential for viral replication.

  DOI：

  10.1021/jm301778x

文献信息

• [EN] CONDENSED PYRIMIDINE NUCLEOSIDE ANALOGS AS ANTI -VIRAL AGENTS<br/>[FR] ANALOGUES DE NUCLÉOSIDES DE PYRIMIDINE CONDENSÉS EN TANT QU'AGENTS ANTIVIRAUX
  申请人：UNIV CARDIFF

  公开号：WO2013007992A1

  公开（公告）日：2013-01-17

  3-(2',3'-dideoxy-ribo-β-L-furanosyl)[2,3-d]pyrimidin-2(3H)-one derivatives comprising 6-substitutents on the base moiety are shown to have anti-viral properties, particularly with respect to vaccinia and measles. The compounds have unnatural L ribose stereochemistry.

  已知在嘌呤碱基部分具有6-取代基的3-(2',3'-二去氧-β-L-呋喃核苷基)[2,3-d]嘧啶-2(3H)-酮衍生物具有抗病毒性能，特别是针对天花病毒和麻疹病毒。这些化合物具有非天然的L核糖立体化学结构。
• Amino alcohol compound
  申请人：Nishi Takahide

  公开号：US20070191468A1

  公开（公告）日：2007-08-16

  A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): [Chemical Formula 1] (wherein R 1 represents a methyl group or an ethyl group, R 2 represents a methyl group or an ethyl group, and R 3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

  提供了一种低毒性、表现出优越的物理化学性质和药代动力学，并具有优越的外周血淋巴细胞计数降低活性的药物组合物。该药物组合物包含具有一般式（I）的化合物：[化学式1]（其中R1代表甲基基团或乙基基团，R2代表甲基基团或乙基基团，R3代表苯基，该苯基被1至3个取自卤原子、较低烷基基团、环烷基团、较低烷氧基团、卤代较低烷基基团、较低脂肪酰基基团和氰基的取代基所取代），以及其药理学上可接受的盐或药理学上可接受的酯。
• AMINO ALCOHOL COMPOUND
  申请人：Sankyo Company, Limited

  公开号：EP1733724A1

  公开（公告）日：2006-12-20

  A pharmaceutical composition is provided that has a low toxicity, demonstrates superior physicochemical properties and pharmacokinetics, and has superior peripheral blood lymphocyte count lowering activity. The pharmaceutical composition contains a compound having general formula (I): (wherein R1 represents a methyl group or an ethyl group, R2 represents a methyl group or an ethyl group, and R3 represents a phenyl group substituted with 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halogeno lower alkyl group, a lower aliphatic acyl group and a cyano group), a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof.

  本研究提供了一种药物组合物，它具有低毒性、优异的理化性质和药代动力学特性，并具有优异的降低外周血淋巴细胞计数的活性。 该药物组合物含有通式（I）的化合物： (其中 R1 代表甲基或乙基，R2 代表甲基或乙基，R3 代表被 1 至 3 个选自卤素原子、低级烷基、环烷基、低级烷氧基、卤代低级烷基、低级脂肪酰基和氰基的取代基取代的苯基）、其药理学上可接受的盐或其药理学上可接受的酯。
• US7910617B2
  申请人：——

  公开号：US7910617B2

  公开（公告）日：2011-03-22
• US8551966B2
  申请人：——

  公开号：US8551966B2

  公开（公告）日：2013-10-08